Advertisement

Overall Survival in the OlympiA Trial of Adjuvant Olaparib
Posted: 03/30/2022 | By: Sarah Campen, PharmD

Question 1 of 5

Which statement is TRUE regarding the OlympiA study?

Choose 1

A
It is the first phase III randomized clinical trial testing a PARP inhibitor as neoadjuvant therapy
B
The trial included patients with germline BRCA1/2 mutation–associated, HER2-negative early breast cancer
C
The double-blind trial compared the efficacy of olaparib with talazoparib
D
In the latest interim analysis, two additional cases of myelodysplastic syndrome and one case of acute myeloid leukemia were reported with the use of olaparib

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage